Julie M. Vose, MD, MBA, highlights the push toward gender diversity in medical oncology.
There has been growth in the representation of women in many areas of medicine. For example, in 2017, for the first time, more women than men matriculated into United States medical schools.1 However, women remain underrepresented in academic medicine as well as leadership positions in academic medicine.2 The theory has been that it just takes time for women to go through the ranks and they can gain representation as time goes on. Although this has happened to some degree, with the major increase in women going through medical training, more representation would be expected at this point.
In hematology/oncology, this trend is evident, with slow improvements over the past several decades. For example, of the 59 presidents of the American Society of Clinical Oncology (ASCO), only 9 have been women. However, 4 of the past 10 have been women. Such slow improvement is evident at every level of academic oncology, especially over the past decade. Another example is the exceptionally low level of representation of women on editorial boards of major medical journals, and the near total lack of women as editors-in-chief for major oncology journals.3 The lack of women in these positions is multifactorial and individual for each situation. However, the modifiable determinants should be addressed on an individual basis. When positions become available, a broad net should be cast for applicants, with specific outreach to qualified candidates in underrepresented categories.
In some exceptional circumstances, traditional expectations need to be modernized to meet candidates’ needs. This could include flexible hours, improved clinical or administrative support, or a modified career plan timeline considering family and personal needs. The one-size-fits-all academic and clinical entity approach does not work well for the diversification of physicians or the growth of the hematology/oncology specialty. It is incumbent on the few women in leadership positions in hematology/oncology to change the trajectory for the future of women in the field.
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.